

097H  
W952



SYSTEMIC OXIDANT STRESS AND ITS EFFECTS ON  
HEPATOTOXICITY

A thesis submitted for  
the degree of

DOCTOR OF PHILOSOPHY

*in*

The Department of Clinical & Experimental Pharmacology  
The University of Adelaide, South Australia.

*by*

Paul F.A. Wright, B.Sc.(Hons.)

August 1988

## ABSTRACT

Experimental work which concerned certain aspects of oxyradical formation *in vitro* by a cell type involved in systemic oxidant stress, and the effect of inflammation-induced systemic oxidant stress on hepatotoxicity *in vivo*, produced the results detailed below.

1. A sensitive and specific HPLC-amperometric assay for hydroxylated salicylate was developed for the detection of hydroxyl radicals ( $\text{OH}\cdot$ ). The sensitivity of the assay was attributable to the optimisation of extraction and storage procedures, and the use of electrochemical detection of the reaction products. Both specificity and sensitivity compared favourably with the [ $^{14}\text{C}$ ]-benzoate decarboxylation assay in the ferrous-EDTA autoxidation and xanthine oxidase-hypoxanthine-ferric-EDTA systems. This assay was sufficiently sensitive to measure  $\text{OH}\cdot$  formation in isolated cellular systems.

2. Human neutrophils (PMN) activated by either serum treated zymosan (STZ), phorbol myristate acetate (PMA), formyl-methionyl-leucyl-phenylalanine (with cytochalasin B) or A23187, produce a partially reduced oxygen species capable of hydroxylating salicylate to form dihydroxybenzoates (DHB), as determined by HPLC/amperometric detection. Irrespective of the stimulus, the hydroxylation was markedly inhibited by superoxide dismutase but not catalase. Azide selectively inhibited DHB formation in PMN

activated with STZ (a potent degranulating agent which stimulates myeloperoxidase release), but had less effect on PMA-stimulated hydroxylation. Desferrioxamine failed to inhibit DHB production suggesting that it is independent of the Fenton reaction. Taken together with the lack of inhibitory effect of chelating agents, the data suggest that salicylate is hydroxylated by PMN *in vitro* by a highly reactive species, probably the OH<sup>•</sup>. This hydroxylating species is superoxide- and myeloperoxidase-dependent and is formed by a Fenton reaction-independent mechanism. Therefore two phagocytic functions - the respiratory burst and degranulation, may interact to produce a toxic species in addition to the hypochlorite ion.

3. Systemic oxidant stress is a condition in which an excess of oxyradical production can lead to altered cellular antioxidant levels and other responses. It was induced in LACA Swiss mice, albino Porton and hooded Wistar rats, by the tail-base injection of the acute inflammogen, oleyl alcohol (OA), or the chronic inflammogen, adjuvant (ADJ, *Mycobacterium tuberculosis* in squalane). The resultant effects included the inhibition of the hepatic microsomal mixed function oxidase (MMFO) profiles in a temporally phasic manner. Hepatic MMFO activity was assessed *in vivo* by pentobarbital sleeping times (PST) and zoxazolamine paralysis times; and *in vitro* by ethoxycoumarin O-deethylation and diphenylloxazole hydroxylation activities.

The injection of inflammogens also resulted in decreased in body weight and fluctuations in hepatic glutathione levels.

Paracetamol-induced hepatotoxicity was ameliorated by the presence of inflammation, however hepatotoxicity induced by bromobenzene was unaffected (assessed by serum alanine aminotransferase). The effects induced by the arthritogenic ADJ treatment were more prolonged than those caused by the short-term inflammogen OA (particularly in the hooded rat). The differential effect of inflammation on two oxidative-microsomal activated hepatotoxins precludes the assumption that all MMFO-activated compounds would be affected in a similar manner by the presence of systemic oxidant stress.

4. Concomitant piroxicam administration repeatedly and specifically attenuated OA-mediated effects on the liver - daily dosage reduced OA-induced PST prolongation (Swiss mice and hooded rats) and OA-mediated ceruloplasmin synthesis (hooded rats); and restored PC-induced hepatotoxicity in OA-inflamed Swiss mice. Clozic administration reduced the inflammation-mediated effects on PC-induced hepatotoxicity in both OA and ADJ treated Swiss mice. The immunological status of Swiss mice and C3H/HeJ mice during OA and/or piroxicam treatment, which was assessed by *ex vivo* lymphocyte proliferation, suggested the presence of high levels of PGE<sub>2</sub> and functionally equivalent levels of IL-1; whereas ADJ treatment caused the production of mainly IL-1.

From these results it may be concluded that: (a) inflammation induced by OA is accompanied by large increases in PGE<sub>2</sub> and IL-1 levels which stimulates the liver (via another cytokine, IL-6) to produce Acute Phase Reactants, turn down certain MMFO systems, and cause fluctuations in hepatic glutathione levels; (b) ADJ-induced inflammation is accompanied by increases in IL-1 predominantly which promotes the same hepatic changes seen with OA treatment (also via IL-6), but in a piroxicam-insensitive (and therefore PGE<sub>2</sub>-insensitive) manner. (c) Clozic interacts with presently unknown cytokines common to both pathways. (d) Piroxicam exhibits immunostimulatory action by inducing lymphocyte proliferation in OA-treated mice.

## CONTENTS

	Declaration.....	i
	Acknowledgements.....	ii
	Dedication.....	iii
	Abstract.....	iv
	Aims of this study.....	viii
	Abbreviations.....	ix
<b>1</b>	<b>GENERAL INTRODUCTION</b>	<b>1</b>
	1.1 Reactive oxygen species.....	2
	1.2 Protective mechanisms against oxyradicals.....	5
	1.3 Oxidant stress.....	6
	1.4 Inflammation-induced oxidant stress.....	9
	1.5 Hepatic changes during inflammation.....	10
	1.6 Metabolism of xenobiotics in the liver.....	11
<b>2</b>	<b>HPLC-ECD ASSAY OF HYDROXYLATED SALICYLATE FOR THE DETECTION OF HYDROXYL RADICALS.</b>	<b>14</b>
	2.1 Introduction.....	15
	2.2 Incubation systems for OH <sup>•</sup> fluxes.....	19
	2.2.1 Quantitation by chemiluminescence....	19
	2.3 HPLC-ECD assay method.....	22
	2.4 Aspects of assay sensitivity.....	22
	2.4.1 Hydrodynamic voltammogram.....	22
	2.4.2 Standard curve of DHB.....	24
	2.4.3 Assay variability and limit of sensitivity.....	24
	2.4.4 Sample stability.....	26
	2.5 Aspects of assay specificity.....	31
	2.5.1 Specificity in the xanthine oxidase/ hypoxanthine system.....	31
	2.5.2 Comparison with <sup>14</sup> C-benzoate decarboxylation assay.....	34

2.5.3	Other products of OH <sup>•</sup> fluxes.....	38
2.6	Discussion.....	39
<b>3</b>	<b>HYDROXYLATION OF SALICYLATE BY ACTIVATED HUMAN NEUTROPHILS: EVIDENCE OF A ROLE FOR SUPEROXIDE AND MYELOPEROXIDASE.....</b>	<b>47</b>
3.1	Introduction.....	48
3.2	Methods.....	51
3.2.1	Preparation of neutrophils.....	51
3.2.2	Preparation of stimuli and inhibitors.....	52
3.2.3	<i>In vitro</i> hydroxylation of salicylate.	53
3.2.4	Measurement of superoxide production by PMN.....	53
3.3	Results.....	54
3.3.1	Formation of DHB by PMN.....	54
3.3.2	Effects of catalase, superoxide dismutase and diphenylene iodonium on DHB formation by PMN.....	59
3.3.3	Effects of azide.....	63
3.3.4	Effects of iron chelators and ascorbate.....	63
3.4	Discussion.....	66
<b>4</b>	<b>MODIFICATION OF HEPATOTOXICITY BY INFLAMMATION- INDUCED SYSTEMIC OXIDANT STRESS.....</b>	<b>77</b>
4.1	Introduction.....	78
4.2	Methods.....	81
4.2.1	Acute and chronic inflammation.....	81
4.2.2	<i>In vivo</i> assessments of hepatic microsomal mixed function oxidases...	81
4.2.3	<i>In vitro</i> assessments of MMFO activities.....	83
4.2.4	Determination of hepatic non-protein sulphydryls.....	84

4.2.5	Administration of hepatotoxic probes.	85
4.2.6	Determination of serum alanine aminotransferase activity.....	85
4.3	Results.....	86
4.3.1	The effect of inflammation on MMFO activity <i>in vivo</i> .....	86
4.3.2	The effect of inflammation on MMFO activity <i>in vitro</i> .....	99
4.3.3	The effect of inflammation on hepatic non-protein sulphhydryl levels.....	99
4.3.4	The effect of inflammation on the hepatotoxic responses to paracetamol and bromobenzene.....	103
4.4	Discussion.....	107
5	<b>MODIFICATION BY ANTI-INFLAMMATORY DRUGS OF SYSTEMIC OXIDANT STRESS AND ITS EFFECTS ON HEPATOTOXIC RESPONSES.....</b>	<b>118</b>
5.1	Introduction.....	119
5.2	Methods.....	125
5.2.1	Administration of anti-inflammatory drugs.....	125
5.2.2	<i>In vivo</i> assessments of hepatic MMFO..	125
5.2.3	Administration of hepatotoxic probes.	126
5.2.4	Determination of serum alanine aminotransferase activity.....	126
5.2.5	Determination of serum ceruloplasmin activity.....	126
5.2.6	Isolation of immunological cell types.....	127
5.2.7	Immunological parameters.....	128
5.2.7.1	<i>Ex vivo</i> proliferation.....	128
5.2.7.2	IL-1 production by peritoneal macrophages.....	128



5.2.7.3	IL-2 stimulated cell proliferation.....	129
5.3	Results.....	129
5.3.1	The effects of anti-inflammatory drugs on the <i>in vivo</i> hepatic pentobarbital metabolism by inflamed animals.....	129
5.3.2	The effects of anti-inflammatory drugs on the hepatotoxic response of inflamed Swiss mice.....	132
5.3.3	The effects of piroxicam and clozic administration with inflammogen treatment on serum ceruloplasmin activity.....	135
5.3.4	The effects of piroxicam on the <i>ex vivo</i> proliferation of lymphocytes from inflamed mice.....	138
5.3.5	Effects of inflammogens and piroxicam on IL-1 production by peritoneal macrophages.....	145
5.3.6	Effects of inflammogens and piroxicam on IL-2 stimulated lymphocyte proliferation.....	145
5.4	Discussion.....	150
6	<b>GENERAL CONCLUSIONS.....</b>	<b>151</b>
	<b>REFERENCES.....</b>	<b>162</b>
	<b>APPENDIX: Sources of drugs and chemicals.....</b>	<b>175</b>